VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-2.98%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$251M
AUM Growth
-$19M
(-7%)
Cap. Flow
-$3.64M
Cap. Flow
% of AUM
-1.45%
Top 10 Holdings %
Top 10 Hldgs %
7.1%
Holding
477
New
43
Increased
256
Reduced
137
Closed
41
Top Buys
| 1 |
The Mosaic Company
MOS
|
$900K |
| 2 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
$877K |
| 3 |
Enphase Energy
ENPH
|
$858K |
| 4 |
Gartner
IT
|
$732K |
| 5 |
Devon Energy
DVN
|
$727K |
Top Sells
| 1 |
L3Harris
LHX
|
$740K |
| 2 |
Cheniere Energy
CQP
|
$732K |
| 3 |
Agilent Technologies
A
|
$713K |
| 4 |
Copart
CPRT
|
$688K |
| 5 |
Equifax
EFX
|
$678K |
Sector Composition
| 1 | Healthcare | 18.83% |
| 2 | Real Estate | 17.55% |
| 3 | Materials | 12.77% |
| 4 | Financials | 9.88% |
| 5 | Energy | 9.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
AbCellera Biologics
ABCL
$1.24B
| $117K | 0.05% |
11,876
+92
| +0.8% | +$906 |
|
402
CRISPR Therapeutics
CRSP
$4.8B
| $117K | 0.05% |
1,795
+11
| +0.6% | +$717 |
|
403
GH Research
GHRS
$872M
| $117K | 0.05% |
10,026
+74
| +0.7% | +$864 |
|
|
PNT
404
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $117K | 0.05% |
15,135
+106
| +0.7% | +$819 |
|
|
SRNE
405
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $116K | 0.05% |
74,087
+540
| +0.7% | +$845 |
|
406
Kodiak Sciences
KOD
$452M
| $113K | 0.05% |
14,555
+102
| +0.7% | +$792 |
|
407
Nkarta
NKTX
$151M
| $113K | 0.05% |
8,576
+62
| +0.7% | +$817 |
|
408
Cullinan Oncology
CGEM
$408M
| $111K | 0.04% |
8,686
+66
| +0.8% | +$843 |
|
|
ITOS
409
DELISTED
iTeos Therapeutics
ITOS
| $111K | 0.04% |
5,828
+38
| +0.7% | +$724 |
|
410
Zymeworks
ZYME
$1.07B
| $111K | 0.04% |
17,980
+132
| +0.7% | +$815 |
|
|
NGM
411
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $109K | 0.04% |
8,327
+64
| +0.8% | +$838 |
|
412
ATAI Life Sciences
ATAI
$977M
| $107K | 0.04% |
32,341
+235
| +0.7% | +$777 |
|
413
CION Investment
CION
$537M
| $107K | 0.04% |
+12,643
| New | +$107K |
|
414
Blackstone Secured Lending
BXSL
$6.78B
| $106K | 0.04% |
+4,676
| New | +$106K |
|
415
Merus
MRUS
$5.01B
| $105K | 0.04% |
5,220
+37
| +0.7% | +$744 |
|
416
Dynavax Technologies
DVAX
$1.17B
| $104K | 0.04% |
9,970
+66
| +0.7% | +$688 |
|
417
Kura Oncology
KURA
$706M
| $104K | 0.04% |
7,650
+58
| +0.8% | +$788 |
|
418
Instil Bio
TIL
$205M
| $104K | 0.04% |
1,070
+7
| +0.7% | +$680 |
|
419
Zentalis Pharmaceuticals
ZNTL
$128M
| $104K | 0.04% |
4,819
+33
| +0.7% | +$712 |
|
420
Arcutis Biotherapeutics
ARQT
$1.94B
| $101K | 0.04% |
5,275
+43
| +0.8% | +$823 |
|
421
Madrigal Pharmaceuticals
MDGL
$9.61B
| $99K | 0.04% |
1,519
+15
| +1% | +$978 |
|
|
AFMD
422
DELISTED
Affimed
AFMD
| $95K | 0.04% |
4,601
+33
| +0.7% | +$681 |
|
423
Repare Therapeutics
RPTX
$72.6M
| $93K | 0.04% |
7,637
+51
| +0.7% | +$621 |
|
424
Vir Biotechnology
VIR
$714M
| $91K | 0.04% |
4,695
+36
| +0.8% | +$698 |
|
|
RETA
425
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $91K | 0.04% |
3,604
+25
| +0.7% | +$631 |
|